HKD 0.07
(-5.71%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 177.1 Million HKD | -30.35% |
2022 | 254.28 Million CNY | -66.04% |
2021 | 748.68 Million CNY | -10.81% |
2020 | 839.4 Million CNY | 173.41% |
2019 | 307.01 Million CNY | -28.28% |
2018 | 428.07 Million CNY | 2.89% |
2017 | 416.04 Million CNY | 23.51% |
2016 | 336.85 Million CNY | 75.54% |
2015 | 191.89 Million CNY | -7.39% |
2014 | 207.2 Million CNY | 42.06% |
2013 | 145.85 Million CNY | 39.2% |
2012 | 104.78 Million CNY | -26.27% |
2011 | 142.11 Million CNY | -13.25% |
2010 | 163.81 Million CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 142.84 Million CNY | 0.0% |
2023 Q2 | 268.3 Million CNY | 0.0% |
2023 Q4 | 177.1 Million HKD | 0.0% |
2023 FY | 177.1 Million HKD | -30.35% |
2022 Q2 | 2.31 Billion CNY | 0.0% |
2022 FY | 254.28 Million CNY | -66.04% |
2022 Q4 | 254.28 Million CNY | 0.0% |
2021 Q4 | 610.61 Million CNY | 0.0% |
2021 Q2 | 645.5 Million CNY | 0.0% |
2021 FY | 748.68 Million CNY | -10.81% |
2020 Q2 | 446.15 Million CNY | 0.0% |
2020 FY | 839.4 Million CNY | 173.41% |
2020 Q4 | 706.6 Million CNY | 0.0% |
2019 FY | 307.01 Million CNY | -28.28% |
2019 Q2 | 376.64 Million CNY | 0.0% |
2019 Q4 | 307.01 Million CNY | 0.0% |
2018 FY | 428.07 Million CNY | 2.89% |
2018 Q2 | 411.19 Million CNY | 0.0% |
2018 Q4 | 428.07 Million CNY | 0.0% |
2017 Q4 | 416.04 Million CNY | 0.0% |
2017 Q2 | 278.68 Million CNY | 0.0% |
2017 FY | 416.04 Million CNY | 23.51% |
2016 Q4 | 336.85 Million CNY | 0.0% |
2016 Q2 | 184.56 Million CNY | 0.0% |
2016 FY | 336.85 Million CNY | 75.54% |
2015 FY | 191.89 Million CNY | -7.39% |
2015 Q4 | 191.89 Million CNY | 0.0% |
2015 Q2 | 211.73 Million CNY | 0.0% |
2014 Q2 | 245.17 Million CNY | 0.0% |
2014 FY | 207.2 Million CNY | 42.06% |
2014 Q4 | 207.2 Million CNY | 0.0% |
2013 Q2 | 152.87 Million CNY | 0.0% |
2013 Q4 | 145.85 Million CNY | 0.0% |
2013 FY | 145.85 Million CNY | 39.2% |
2012 Q2 | 141.82 Million CNY | 0.0% |
2012 Q4 | 104.78 Million CNY | 0.0% |
2012 FY | 104.78 Million CNY | -26.27% |
2011 Q4 | 142.11 Million CNY | 0.0% |
2011 Q2 | 267.47 Million CNY | 0.0% |
2011 FY | 142.11 Million CNY | -13.25% |
2010 FY | 163.81 Million CNY | 0.0% |
2010 Q4 | 163.81 Million CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Natural Beauty Bio-Technology Limited | 308.05 Million HKD | 42.508% |
Innovative Pharmaceutical Biotech Limited | 1.06 Billion HKD | 83.348% |
China Overseas Nuoxin International Holdings Limited | 109.1 Million HKD | -62.335% |
Huasheng International Holding Limited | 675.58 Million HKD | 73.784% |
Fourace Industries Group Holdings Limited | 61.8 Million HKD | -186.561% |
Evergreen Products Group Limited | 786.46 Million HKD | 77.48% |
EC Healthcare | 2.97 Billion HKD | 94.037% |
Ming Fai International Holdings Limited | 772.01 Million HKD | 77.059% |
Blue Moon Group Holdings Limited | 1.61 Billion HKD | 89.053% |
SuperRobotics Holdings Limited | 172.27 Million HKD | -2.808% |
Takbo Group Holdings Limited | 42.84 Million HKD | -313.333% |
Hyfusin Group Holdings Limited | 181.34 Million HKD | 2.337% |